Sign In
Buy IDYA
$28.40
+0.530 (+1.90%)
At Close: Jun 03, 2026
IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
06:00am, Monday, 25'th Aug 2025
SOUTH SAN FRANCISCO, Calif. , Aug. 25, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted thera
IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025
06:00am, Monday, 18'th Aug 2025
SOUTH SAN FRANCISCO, Calif. , Aug. 18, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap
IDEAYA (IDYA) Q2 Net Loss Improves 27%
04:23pm, Tuesday, 05'th Aug 2025
IDEAYA Biosciences (IDYA -3.52%), a precision oncology company focused on developing targeted therapies for cancer, reported its second-quarter earnings on August 5, 2025. The company did not report a
Ideaya Biosciences: Moving Into ADCs For Solid Tumors
08:43am, Tuesday, 05'th Aug 2025
IDEAYA Biosciences' recent pipeline updates highlight promising clinical trial results, strengthening my confidence in their long-term growth potential. A robust financial position supports ongoing R&
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
06:00am, Tuesday, 05'th Aug 2025
Phase 2/3 trial of the darovasertib and crizotinib combination in 1L HLA-A2-negative metastatic uveal melanoma (MUM) on track to report median PFS data by year-end 2025; potential to enable a U.S. acc
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06:00am, Friday, 01'st Aug 2025
SOUTH SAN FRANCISCO, Calif. , Aug. 1, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape
The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohorts Darovasertib has received U.S. FDA Breakthrough Therapy Designation for use i
SOUTH SAN FRANCISCO, Calif. , July 23, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap
Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1 trial Data will include patients from the d
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
06:00am, Monday, 21'st Jul 2025
SOUTH SAN FRANCISCO, Calif. , July 21, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06:00am, Friday, 27'th Jun 2025
SOUTH SAN FRANCISCO, Calif. , June 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events
06:00am, Monday, 02'nd Jun 2025
SOUTH SAN FRANCISCO, Calif. , June 2, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06:00am, Friday, 30'th May 2025
SOUTH SAN FRANCISCO, Calif. , May 30, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape
Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849
05:30pm, Wednesday, 14'th May 2025
Ideaya Biosciences, Inc. is advancing darovasertib in a phase 2/3 trial for HLA-A2-negative metastatic uveal melanoma patients, with mPFS data expected by end of 2025. Ideaya plans a phase 3 study of
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
06:05am, Tuesday, 06'th May 2025
~$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enroll
